Research
FORUM TRANSCRIPT

Science 37 – Decentralised Clinical Trials Industry – Q4 2021 Update & Product Portfolio Overview – 12 October 2021

  • Private Equity
  • Healthcare
  • North America
PREMIUM

Specialist

Former Director at Science 37 Inc

Agenda

  • Trends and developments in the virtual and hybrid clinical trial industry, focusing on Science
  • Patient recruitment and retention dynamics and potential cost and time savings of virtual and hybrid vs bricks-and-mortar clinical trials
  • Science 37’s software vs services offerings portfolio, including needed improvements for the latter
  • Potential M&A expectations for Science 37 and possible synergies with a CRO (contract research organisation) acquirer

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo